Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 28, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 525,000 Ordinary shares of 25 pence each.
- Purchase Date: March 28, 2012.
- Price Range: Highest price paid was 1,440 pence per share; lowest price paid was 1,426 pence per share.
- Treasury Holdings (Settled): 515,117,927 shares (9.27% of total issued share capital).
- Treasury Holdings (Including Unsettled): 517,042,927 shares (10.25% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,044,087,403 shares.
Material Changes
The filing reports an incremental increase in the Company's Treasury share holdings following the purchase of 525,000 shares. No other material changes to operations or financial position are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks and voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (515,117,927 settled) against the latest quarterly or annual report.
- Confirm the total issued share capital to validate the 9.27% Treasury ownership percentage.
- Check subsequent filings for the settlement status of the 1,925,000 shares included in the "unsettled" count (difference between 517,042,927 and 515,117,927).
- Review the Annual General Meeting minutes from May 5, 2011, to confirm the remaining authority for future share repurchases.